The Lynx Group
Cholangiocarcinoma News

FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma

June/July 2021, Vol 2, No 2

The FDA granted accelerated approval to the kinase inhibitor infigratinib (Truseltiq) for the treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma (CCA) that harbors an FGFR2 fusion or other rearrangement.

The approval was based on efficacy results from a phase 2, multicenter, open-label, single-arm clinical trial in which 108 patients with unresectable locally advanced or metastatic CCA and an FGFR2 fusion or rearrangement were treated with once-daily oral infigratinib 125 mg in 28-day cycles (21 consecutive days of treatment, followed by 7 days with no treatment).

All patients had received ≥1 previous treatments for CCA. For the trial, treatment continued until disease progression or unacceptable toxicity. Nearly all (99%) patients in the trial had stage IV CCA.

The primary study end points were overall response rate (ORR) and the duration of response (DOR), as determined by blinded Independent Central Review according to RECIST version 1.1.

The ORR was 23% (95% confidence interval [CI], 16-32), which included 24 partial responses and 1 complete response.

The median DOR was 5 months (95% CI, 3.7-9.3), with 8 of 23 responders maintaining a response for ≥6 months.

In a news release from QED Therapeutics and Helsinn Group that accompanied the FDA approval of infigratinib, Susan Moran, MD, MSCE, Chief Medical Officer for QED Therapeutics, said, “This is an important milestone for patients diagnosed with FGFR2 fusion–driven cholangiocarcinoma who have recurred after first-line therapy and are in need of targeted options for further treatment. Based on the efficacy seen to date, our team believes infigratinib possesses promise for a range of FGFR-driven conditions, including other cancers.”

During the study, the most common adverse reactions (observed in ≥20% of patients) were hyperphosphatemia, increased creatinine, nail toxicity, stomatitis, dry eye, fatigue, alopecia, palmar-plantar erythrodysesthesia syndrome, arthralgia, dysgeusia, constipation, abdominal pain, dry mouth, eyelash changes, diarrhea, dry skin, decreased appetite, vision blurred, and vomiting.

Serious risks identified in the study include hyperphosphatemia and retinal pigment epithelial detachment.

CCA News Editor-in-Chief Milind M. Javle, MD, Professor of Gastrointestinal Medical Oncology at The University of Texas M.D. Anderson Cancer Center, presented these study results at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

In the news release related to the FDA approval, Dr Javle noted that although “targeted treatments have extended survival for many types of cancer, people diagnosed with cholangiocarcinoma have previously been presented with extremely limited treatment options coupled with low statistical survival data.”

These study results confirmed that “infigratinib showed promise as a targeted treatment option for patients with FGFR2 fusion–driven cholangiocarcinoma with a well-tolerated safety profile in line with previous observations in this patient population,” Dr Javle added.

Related Items

2022 Year in Review: Cholangiocarcinoma
By Richard Kim, MD
2022 Year in Review: Cholangiocarcinoma
In 2022, the COVID-19 pandemic continued to impact the practice of medicine and dissemination of treatment advances presented in scientific forums. Adapting to the changes, societies such as the American Society of Clinical Oncology, Gastrointestinal Cancers Symposium, and European Society for Medical Oncology have adopted virtual and hybrid formats that deliver cutting-edge research in the advancement of oncology care. Recognizing the challenges of the virtual and hybrid formats in terms of reach and impact, we are bringing the Year in Review series that seeks to disseminate key information on treatment advances to clinicians in a timely and effective manner.
Durvalumab plus GemCis in Advanced BTC: A New Standard-of-Care?
2022 Year in Review: Cholangiocarcinoma
Phase 3 TOPAZ-1 clinical trial established durvalumab plus gemcitabine/cisplatin as a viable first-line standard-of-care treatment regimen for advanced biliary tract cancer.
Updated Results from the FOENIX-CCA2 Trial of Futibatinib in Patients with iCCA Harboring FGFR2 Fusions/Rearrangements
2022 Year in Review: Cholangiocarcinoma
Updated FOENIX-CCA2 trial results were found to be consistent with the primary analysis, indicating durable efficacy and continued tolerability of futibatinib in patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions/rearrangements.
Results from the BilT-04 Study: First-Line GemCis with or without CPI-613 in Advanced BTCs
2022 Year in Review: Cholangiocarcinoma
The BilT-04 study revealed that the addition of CPI-613 to gemcitabine/cisplatin was well-tolerated with potential activity in patients with advanced biliary tract cancers.
Final Results from the FIGHT-202 Trial of Pemigatinib in Metastatic CCA
2022 Year in Review: Cholangiocarcinoma
Final analysis of the phase 2 FIGHT-202 trial demonstrated durable response and a tolerable safety profile for pemigatinib in patients with metastatic cholangiocarcinoma.
Updated Results from the TOPAZ-1 Study of Durvalumab plus GemCis in Patients with Advanced BTC
2022 Year in Review: Cholangiocarcinoma
Updated data from the TOPAZ-1 study revealed improved median overall survival for the full patient population and no new safety signals.
TOPAZ-1 Trial Subanalysis: Outcomes by Primary Tumor Location in Advanced BTCs
2022 Year in Review: Cholangiocarcinoma
Subanalysis of the phase 3 TOPAZ-1 trial found that durvalumab plus gemcitabine/cisplatin showed efficacy as a treatment regimen in patients with biliary tract cancer regardless of primary tumor location.
Early Data from the ReFocus Trial
2022 Year in Review: Cholangiocarcinoma
Early data from the ReFocus trial indicated that RLY-4008 may be an effective new treatment for patients with cholangiocarcinoma harboring FGFR2 fusions or rearrangements.
Results from the Phase 2 NEO-GAP Trial: Neoadjuvant Gemcitabine/Cisplatin/Nab-Paclitaxel for Resectable High-Risk iCCA
2022 Year in Review: Cholangiocarcinoma
NEO-GAP investigators found neoadjuvant gemcitabine/cisplatin/nab-paclitaxel combination to be feasible and safe prior to curative-intent surgical resection in patients with intrahepatic cholangiocarcinoma.
Preliminary Results from the FIDES-01 Trial: Derazantinib as a Second-Line Treatment for iCCA with FGFR2 Alterations
2022 Year in Review: Cholangiocarcinoma
The FIDES-01 clinical trial showed encouraging preliminary results for derazantinib as a second-line treatment in patients with intrahepatic cholangiocarcinoma harboring FGFR2 alterations.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: